Financial reports
ARS
2023 FY
Annual report to shareholders
1 Apr 24
10-K
2023 FY
Annual report
15 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
3 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
10-Q
2022 Q1
Quarterly report
28 Apr 22
Current reports
8-K
Departure of Directors or Certain Officers
4 Mar 24
8-K
Results of Operations and Financial Condition
15 Feb 24
8-K
Departure of Directors or Certain Officers
19 Jan 24
8-K
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
8 Jan 24
8-K
Results of Operations and Financial Condition
2 Nov 23
8-K
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
10 Oct 23
8-K
Departure of Directors or Certain Officers
28 Sep 23
8-K
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
3 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jul 23
8-K
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
30 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
23 Feb 23
S-8
Registration of securities for employees
11 Feb 21
S-3ASR
Automatic shelf registration
5 Jun 20
S-8
Registration of securities for employees
13 Feb 20
424B5
Prospectus supplement for primary offering
15 Jan 19
424B5
Prospectus supplement for primary offering
14 Jan 19
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Aug 18
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Aug 18
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Aug 18
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Aug 18
Proxies
DEFA14A
Additional proxy soliciting materials
1 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEF 14A
Definitive proxy
3 Apr 23
DEFA14A
Additional proxy soliciting materials
5 Apr 22
DEF 14A
Definitive proxy
5 Apr 22
DEFA14A
Additional proxy soliciting materials
2 Apr 21
DEF 14A
Definitive proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
24 Mar 20
DEF 14A
Definitive proxy
23 Mar 20
Other
CT ORDER
Confidential treatment order
14 Feb 23
SEC STAFF
SEC staff action: Order
18 Mar 21
SEC STAFF
SEC staff action: Order
18 Feb 21
CT ORDER
Confidential treatment order
5 Jul 19
CT ORDER
Confidential treatment order
2 May 19
CT ORDER
Confidential treatment order
2 May 19
CT ORDER
Confidential treatment order
2 May 19
CT ORDER
Confidential treatment order
10 Apr 19
UPLOAD
Letter from SEC
21 Mar 19
CT ORDER
Confidential treatment order
12 Sep 18